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introduction: There are relatively few longitudinal studies on the differences in cognitive 
decline between Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB), and 
the majority of existing studies have suboptimal designs.
aim: We investigated the differences in cognitive decline in AD compared to DLB over 
4 years and cognitive domain predictors of progression.
Methods: In a longitudinal study, 266 patients with first-time diagnosis of mild dementia 
were included and followed annually. The patients were tested annually with neuropsy-
chological tests and screening instruments [MMSE (Mini-Mental Status Examination), 
Clinical Dementia Rating (CDR), the second edition of California Verbal Learning Test 
(CVLT-II), Trail Making Test A & B (TMT A & B), Stroop test, Controlled Oral Word 
Associations Test (COWAT) animal naming, Boston Naming Test, Visual Object and 
Space Perception Battery (VOSP) Cubes and Silhouettes]. Longitudinal analyses were 
performed with linear mixed effects (LME) models and Cox regression. Both specific 
neuropsychological tests and cognitive domains were analyzed.
results: This study sample comprised 119 AD and 67 DLB patients. In TMT A, the 
DLB patients had a faster decline over 4 years than patients with AD (p = 0.013). No 
other longitudinal differences in specific neuropsychological tests were found. Higher 
executive domain scores at baseline were associated with a longer time to reach severe 
dementia (CDR = 3) or death for the total sample (p = 0.032). High or low visuospatial 
function at baseline was not found to be associated with cognitive decline (MMSE) or 
progression of dementia severity (CDR) over time.
conclusion: Over 4 years, patients with DLB had a faster decline in TMT A than patients 
with AD, but this should be interpreted cautiously. Beyond this, there was little support 
for faster decline in DLB patients neuropsychologically than in AD patients.
Keywords: dementia with lewy bodies, alzheimer’s disease, cognitive decline, longitudinal, neuropsychology
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inTrODUcTiOn
Dementia with Lewy bodies (DLB) is the second most com-
mon type of neurodegenerative dementias with a prevalence 
of 2.2–24.7% (1). Opposed to Alzheimer’s disease (AD) which 
is associated with tau and amyloid pathology, DLB is an 
α-synucleinopathy, characterized with visual hallucinations, par-
kinsonism, and fluctuations. DLB seems to be a more devastating 
condition following a more malignant disease course than AD, 
with a nearly halved time until nursing home admission implying 
much higher costs and nearly halved survival time. Additionally, 
persons diagnosed with DLB experience more anxiety and sleep 
disturbances than persons diagnosed with AD (2–6).
Previous longitudinal studies have limited evidence base 
mostly due to methodological weaknesses when addressing the 
rate of progression of cognitive decline in DLB as compared to 
AD, and the data are still inconclusive. 6 of 18 studies included 
in our systematic review and meta-analysis reported significant 
differences in the rate of cognitive decline between these two 
conditions. Three studies reported a faster cognitive decline on 
Mini-Mental Status Examination (MMSE) in patients with mixed 
DLB and AD compared to pure forms. Two studies reported a 
faster decline on delayed recall and recognition in AD, and one in 
DLB on verbal fluency. The meta-analysis of six studies reporting 
MMSE scores found no significant difference in annual decline 
between DLB and AD (7). An updated search did not add any 
information, except from three studies that used MMSE as out-
come. For instance, our research group found a faster decline in 
DLB than AD over 5 years (4.4 vs 3.2 points on average per year) 
(8). In the second study, patients with mixed AD and DLB were 
shown to decline faster than AD or DLB, and in the last one, they 
found some indications of a faster decline in DLB than in AD and 
Parkinson’s disease dementia (PDD) (9, 10).
While AD is predominantly characterized by impaired epi-
sodic memory, patients with DLB have more impaired execu-
tive, attentional, and visuospatial functioning. For example, 
visuospatial dysfunction is found in 71% of DLB and in 40% of 
AD, when controlled for motor function (11), and is found to be 
predictive for global cognitive impairment (12). In two studies, 
patients with DLB were divided into groups with high or low 
visuospatial functioning. Patients with low baseline visuospatial 
functioning had a faster decline on the Dementia Rating Scale 
(DRS) and activities of daily living (ADL). No differences were 
found in AD subgroups (12, 13). In our baseline study, we found 
that visuoconstructional functions in DLB were worse than in 
AD, but we did not find any differences between AD and DLB 
regarding visuoperception (14).
There is a lack of robust and reliable longitudinal studies that 
compare the cognitive decline in AD and DLB. Studies are needed 
in order to have a thorough knowledge about prognosis, a very 
important issue for the patients and their caregivers, as well for 
the community that plans caregiving. To complement previous 
research, we investigated (a) differences in rate of decline in neu-
ropsychological test over 4 years in AD and DLB, (b) the associa-
tion of cognitive domains at baseline and dementia progression, 
and (c) the associations of high and low visuospatial function at 
baseline and dementia progression.
MaTerials anD MeThODs
subjects
Totally, 266 outpatients in clinics of old age psychiatry and geriat-
ric medicine in Western Norway with a first-time mild dementia 
diagnosis [MMSE score of at least 20 or Clinical Dementia 
Rating (CDR) 1] were recruited from 2005 and followed annu-
ally. Patients with acute delirium or confusion, terminal illness, 
current or previous bipolar disorder or psychotic disorder, or 
who were recently diagnosed with a major somatic illness were 
excluded (15). Follow-ups were conducted at the clinic or in 
nursing homes. The study protocol was approved by the Regional 
Committee for Medical and Health Research Ethics in Western 
Norway as well as in the Norwegian Social Science Data Services. 
Written informed consent was obtained from all participants.
Measures
Dementia Diagnosis
The diagnosis of dementia was based on Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. 
The diagnosis of Alzheimer’s disease was made according to The 
National Institute of Neurological and Communicative Disorders 
and Stroke-AD and Related Disorders Association (16). DLB 
was diagnosed according to the revised consensus criteria 
(17). Ioflupane single-photon emission computed tomography 
(123I-FP-CIT SPECT) (DaTSCAN) was conducted for 55 patients. 
Two independent raters set the diagnosis, and the diagnoses were 
evaluated after 2 and 5 years, based on all available information 
from follow-ups. Neuropathological confirmations are consecu-
tively sampled. For further diagnostic information see Aarsland 
et al. (15).
Neuropsychological Measures
A battery of standardized and established rating scales and tests 
was used for investigating patients’ cognitive functioning. MMSE 
(18) is a brief test used for screening cognitive impairment. The 
CDR (19) is used for assessing the severity of dementia, on a 
global scale from 0 to 3. The second edition of California Verbal 
Learning Test (CVLT-II) (20) was used for assessing verbal learn-
ing and memory, in addition to MMSE delayed recall. Visual 
scanning, psychomotor speed, and attention were assessed with 
Trail Making Test A & B (TMT A & B) (21). Executive functions 
were also measured by MMSE attention and calculation, Stroop 
test (word, color, color-word, number of correct words read in 
45 s) (22), and Controlled Oral Word Associations Test, using the 
Abbreviations: AD, Alzheimer’s disease; ADL, activities of daily living; BNT, Boston 
Naming Test; BPSD, behavioural and psychological symptoms; CDR, Clinical 
Dementia Rating; CVLT-II, the second edition of California Verbal Learning Test; 
COWAT, Controlled Oral Word Associations Test; DLB, dementia with Lewy 
bodies; DRS, Dementia Rating Scale; DSM-IV, Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition; LB, Lewy bodies; LME, linear mixed effects; 
MCI, mild cognitive impairment; MMSE, Mini-Mental Status Examination; PD, 
Parkinson’s disease; PDD, Parkinson’s disease dementia; TMT A & B, Trail Making 
Test A & B; VOSP, Visual Object and Space Perception Battery; 123I-FP-CIT SPECT, 
ioflupane single-photon emission computed tomography.
FigUre 1 | Flow chart.
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semantic fluency task of naming animals (COWAT) (23). Naming 
was measured with Boston Naming Test (BNT) 15 items (24). 
Visuospatial function was measured by Silhouettes and Cubes 
on the Visual Object and Space Perception Battery (VOSP) (25) 
and the pentagon on MMSE. The memory domain was composed 
of CVLT-II List A 1–5 total, CVLT-II delayed recall and MMSE 
delayed recall. The executive domain of TMT A, Stroop test, 
COWAT naming animals and MMSE attention and calculation, 
and the visuospatial domain of VOSP Silhouettes and Cubes and 
MMSE pentagon.
Raw scores were used when analyzing neuropsychological 
tests. When analyzing cognitive domains, raw scores were stand-
ardized into z-scores, and then computed into a composite score 
for each domain. TMT A was reversed.
Statistical Analyses
Statistical analysis was made with SPSS 22.0. and R (26). 
Differences between AD and DLB at baseline were analyzed with 
Mann–Whitney U-test, T-test for normally distributed data, and 
by Pearson chi-square for categorical data. Linear mixed effects 
(LME) models were employed to analyze the longitudinal data 
to study possible differences between AD and DLB in neuropsy-
chological tests. The LME model is to a certain extent capable 
of handling longitudinal data with dropout (27). Models with 
random intercept and random slope were used. Cox regres-
sion analyses were performed to find out if cognitive domains 
(memory, executive, visuospatial) at baseline were associated 
with survival/dementia severity. Outcome was defined as reach-
ing CDR 3 or death. Finally, we used random effects logistic 
regression, finding the association between probability for CDR 
>1.5 (dementia severity) or lower MMSE score (cognitive 
decline) and as function of time and visuospatial function at 
baseline. High or low function was defined by a domain score 
above or below the mean.
resUlTs
Baseline
Of 266 recruited patients, 186 were included in the analysis, 
119 AD and 67 DLB, see Figure  1 for flow chart. There were 
no significant differences between the groups in age, education, 
depression, MMSE, and CDR scores at baseline. The AD group 
had significantly more women included and the DLB group 
had significantly longer duration of symptoms before inclusion 
(see Table 1).
Follow-up
An association between time, diagnosis, and neuropsychological 
tests was found on Trails A (p = 0.013), where the DLB group 
had a significantly faster decline compared to the AD group (see 
Figure 2). No statistical differences were found in CVLT-II, VOSP, 
BNT, Stroop, COWAT, and TMT A. Analyses were adjusted for 
sex, age, and education (see Table 2).
Higher executive domain scores at baseline were associated 
with a longer time to reach severe dementia (CDR 3) or death for 
the total sample (p = 0.032), but type of dementia were not. No 
such associations were observed for the visuospatial or memory 
domain. The analyses were adjusted for age and sex (see Table 3). 





aAssociations were analyzed with Cox regression and p-values are given.
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies.
FigUre 2 | Differences in Trail Making Test A in Alzheimer’s disease and 
dementia with Lewy bodies over 4 years. Reported in square root 
transformed data.




higher than aD 
at baseline (se)
Differences in 
rate of decline 
per year (se)
p Valuea
CVLT List A 
1–5 total
11.62 (2.94) 2.49 (1.33) −0.99 (0.68) 0.149
CVLT delayed 
recall
−0.68 (0.83) 1.25 (0.38) −0.04 (0.16) 0.805
VOSP 
silhouettes
14.15 (1.85) −1.21 (0.85) −0.36 (0.30) 0.239
BNT 9.72 (1.00) −0.32 (0.46) −0.10 (0.19) 0.595
Stroop word 55.42 (8.15) −22.05 (3.78) −0.21 (1.73) 0.905
Stroop Color 34.95 (6.08) −13.94 (2.81) −0.19 (1.24) 0.881
Stroop 
Color-word
10.50 (3.56) −5.88 (1.65) −0.76 (0.80) 0.341
COWAT 
animals
9.32 (1.50) −1.45 (0.67) −0.28 (0.30) 0.366
Trail Making 
Test A
150.58 (30.46) 50.08 (14.19) −31.77 (10.98) 0.013b
aDifferences in rate between AD and DLB groups were analyzed using Linear mixed 
effects (LME) models.
bLME fit of square root transformed to obtain a satisfactory fit.
AD, Alzheimer’s disease; BNT, Boston Naming Test; CVLT-II, California Verbal Learning 
Test, second edition; COWAT, Controlled Oral Word Associations Test; DLB, dementia 
with Lewy bodies; VOSP, Visual Object and Space Perception Battery.






Age (SD) 75.4 (7.7) 75.8 (7.3) 0.986
Sex, men/women 34/85 36/31 0.001
Education, y (SD) 9.7 (2.9) 9.6 (2.8) 0.820
MMSE (SD) 23.7 (2.4) 23.2 (3.1) 0.340
Duration of symptoms, y (SD) 1.9 (1.8) 2.5 (2.1) 0.041
Depression (SD) 1.9 (2.5) 2.4 (2.8) 0.198
CDR global, mean (SD) 0.8 (0.3) 1.0 (0.5) 0.559
Dementia medication at FU1, y/n 59/60 29/38 0.409
aDifferences between AD and DLB groups were analyzed using the Mann–Whitney 
U-test and Pearson chi-square.
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; MMSE, Mini-Metal Status 
Examination; CDR, Clinical Dementia Rating; FU1, follow up 1; y, years; y/n, yes/no.
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We also analyzed if high or low visuospatial function at baseline 
in AD and DLB were associated with cognitive decline (MMSE) 
(p = 0.108) or dementia severity CDR (p = 0.654), but no differ-
ences were found. The analyses were adjusted for sex, age, and 
education.
At one-year follow-up, only 11.9% (n = 8) of the DLB group 
were able to complete TMT B, compared to 27.7% (n = 33) in the 
AD group, therefore, not included in the analyses.
DiscUssiOn
Patients with DLB had a faster decline on TMT A compared to 
patients with AD over four years. Higher executive function at 
baseline was associated with a slower progression of dementia 
and longer survival in the total group, but no differences between 
AD and DLB were observed. We did not find any association 
between high or low visuospatial function at baseline and the 
rate of decline.
The TMT A task is relatively undemanding cognitively and 
motor tempo determines the performance to a degree. The faster 
decline in the performance of the DLB group could be due to 
more deficiencies in motor and visuospatial functions, which are 
more prominent in DLB than in AD. On the other hand, the two 
groups were progressing without any significant difference on 
other neuropsychological test, some of which were also depend-
ing on such skills. Previous studies have not found differences in 
decline over time between the two groups in TMT A, and due 
to missing data and the risk of familywise statistical error, our 
findings should be cautiously interpreted. In our baseline study, 
we found that DLB patients performed worse than AD on tests 
correlating with parkinsonism, not with visual hallucinations or 
cognitive fluctuation (14).
High executive functions at baseline were associated with 
a slower progression of reaching severe dementia or death for 
the total sample, but there were no differences in progression 
between AD and DLB. In the memory or visuospatial domains, 
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we found no significant differences. Chunking single neuropsy-
chological tests that are assumed to measure more or less the 
same cognitive factor into one cognitive domain has pros and 
cons. We can rely on more tests and presumably a more robust 
measure, nevertheless the domains, especially the executive, are 
not entities, but can be broken into several functions (28). This 
could be the reason why studies of mild cognitive impairment 
have shown mixed results regarding the link between executive 
dysfunctions and prediction of conversion to dementia (29). 
On the other hand, we have not found any studies that have 
investigated the difference in cognitive domains over time in AD 
and DLB. As executive functions also encompass several forms 
of attention, included fluctuations, one of the core symptoms of 
DLB, it would be interesting to find out if patients with DLB and 
relatively preserved executive functions have milder fluctuations 
and a slower disease progression.
Previous research has shown that patients with DLB and low 
visuospatial function have a faster decline on cognitive screening 
tests or ADL function (13). We could not confirm their findings in 
our study. This could possibly be due to longer follow-up time, the 
tests that are used in the analyses, or the lack of neuropathological 
reports on the total sample. Without the neuropathological con-
firmation of the diagnosis, we cannot rule out the possibility that 
there are more DLB cases with neocortical or nigral predominant 
type of LB, and not the limbic type that is more often associated 
with more rapid decline in visuospatial function (30). At the same 
time in AD, the zeitgeist is to move away from using the concept 
AD, and instead refer to the pathology behind the symptoms, 
since there are several subtypes and other AD mimicking diseases 
(31). Lack of systematical differences could hypothetically be due 
to grouping AD patients with mixed pathologies that are not 
identical and the expression of the same disease. We also lack 
information about genetics that could have affected the cognitive 
decline over time.
In clinical practice, the two most frequent and important 
questions for people newly diagnosed with dementia are “is there 
anything that can prevent progression?” followed by “how long 
will it take before I lose my mind?” This is not easy to predict 
for the individual patient, but on group levels, for patients with 
relatively preserved executive functions, the progression seems to 
be slower. Even though there are few studies on neuropsychologi-
cal tests that predict the rate of decline in AD (32), our finding is 
supported from studies that found impaired executive functions 
to be associated with a faster decline (33, 34).
Thus, there is no persuasive evidence that there is a dis-
similar decline in neuropsychological tests and cognitive 
domains between AD and DLB. On the other hand, recent 
studies of good quality have found that DLB progress faster 
than AD and PDD using the cognitive screening test MMSE, 
as outcome. Our clinical impression of a more rapid decline in 
patients with DLB is evident in previously mentioned research, 
probably caused by the α-synuclein pathology and the severe 
BPSD symptoms that are highly frequent in DLB. The cognitive 
differences though, is not the dominant predictor of a more 
rapid disease course (8).
There are some limitations in the study. We have previously 
argued for longer follow up time than 1 year in these kinds of 
studies (7). Regardless a large sample size at baseline, missing data 
is a common issue in longitudinal studies with neurodegenerative 
diseases due to cognitive decline and death. In our study, LME 
models were used to minimize this problem. Also, we used 
neuropsychological test scores at baseline with non-cognitive 
measures as outcome. Another advantage of this approach is 
that in the beginning of the dementia, AD and DLB are more 
separable, since the clinic and brain pathology is more specific, 
not widespread and mixed with brain pathology that comes as a 
natural consequence of aging.
Mini-Mental Status Examination was the only test that all 
the patients could complete at every follow up. MMSE has been 
criticized for not being sensitive enough for measuring changes in 
patients with pure DLB since they have a different cognitive profile 
than AD patients, but Lessig et al. found it valid for Parkinson’s 
disease patients who share most of the same pathology (35).
The mean score at baseline in CVLT-II delayed memory was 
low (mean 1.3 for AD and 2.5 for DLB out of a maximum score of 
16) and missing statistically significant differences could be due 
to floor effect. There is also a potential problem with circularity, 
since the diagnoses are made partially by relying on results on 
cognitive tests (i.e., memory impairments for AD). However, 
the autopsy results indicate that the diagnoses are not biased by 
circularity (36).
Strengths of the study are the longitudinal design with one 
of the largest samples of DLB patients which has been followed 
annually, and the AD and DLB groups were similar in age, educa-
tion, and MMSE score at baseline. The patients are thoroughly 
evaluated and diagnosed, and the majority of the DLB patients 
have undergone 123I-FP-CIT SPECT (DaTSCAN), and DLB is, 
therefore, not likely to be underdiagnosed in the study group. 
Autopsy has been done in 43 cases with 92% sensitivity and 83% 
specificity for clinical diagnosis (36).
cOnclUsiOn
Over 4  years, there was little support for the hypothesis that 
patients with DLB had faster decline neuropsychologically than 
patients with AD. The only exception was TMT A, where patients 
with DLB had a faster decline than AD patients, but this should be 
interpreted cautiously due to missing data and the risk of family-
wise statistical error. Higher executive domain scores at baseline 
were associated with a longer time to reach severe dementia or 
death for the total sample, but type of dementia was not. Further 
research is needed and information about genetics should be 
included.
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